Share chart Sera Prognostics, Inc.
Extended chart
Simple chart
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. more detailsMain settings
IPO date
2021-07-15
ISIN
US81749D1072
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 3505.16 | 1 |
| P/BV | 5.65 | 2 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -39.16 | 0 |
| ROE | -55.78 | 0 |
| ROIC | 0 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0061 | 10 |
| Debt/Ratio | 0.0027 | 10 |
| Debt/Equity | 0.5182 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 208 | 10 |
| Yield Ebitda, % | 87.35 | 9 |
| Yield EPS, % | -16.62 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 1.68 $ | 0 $ | 0 $ | -1.49 % | 0 % | 0 % |
| Week | 1.92 $ | 0 $ | 0 $ | -13.8 % | 0 % | 0 % |
| Month | 3 $ | 1.65 $ | 2.4 $ | -44.83 % | 0 % | 0 % |
| Three month | 4.19 $ | 1.65 $ | 4.29 $ | -60.5 % | 0 % | 0 % |
| Half a year | 6.62 $ | 1.65 $ | 8.78 $ | -75 % | 0 % | 0 % |
| Year | 8.61 $ | 1.65 $ | 8.78 $ | -80.78 % | 0 % | 0 % |
| 3 years | 1.48 $ | 1.16 $ | 11.69 $ | 11.82 % | 0 % | 0 % |
| 5 years | 0 $ | 1.16 $ | 13.04 $ | 0 % | 0 % | 0 % |
| 10 years | 0 $ | 1.16 $ | 13.04 $ | 0 % | 0 % | 0 % |
| Year to date | 7.95 $ | 1.65 $ | 8.33 $ | -79.18 % | 0 % | 0 % |
Main owners
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Ms. Evguenia Lindgardt M.B.A. | President, CEO & Director | 622.42k | 1974 (51 year) |
| Dr. Gregory C. Critchfield M.D., M.S. | Executive Director | 1.04M | 1953 (72 years) |
| Mr. Austin Aerts | Chief Financial Officer | 367.62k | 1987 (38 years) |
| Dr. John J. Boniface Ph.D. | Chief Scientific Officer | 467.32k | 1962 (63 years) |
| Mr. Robert G. Harrison | Chief Information Officer | 384.18k | 1966 (59 years) |
| Mr. Benjamin G. Jackson J.D. | General Counsel | 410.75k | 1979 (46 years) |
| Dr. Paul Kearney Ph.D. | Chief Data Officer | N/A | 1968 (57 years) |
About company
Address: United States, Salt Lake City. UT, 2749 East Parleys Way - Open in google maps, Open in yandex maps
Website: https://seraprognostics.com
Website: https://seraprognostics.com
